Clinical trials: Patients With Cancer
Advanced Solid Tumor
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Phase 1, single-arm, open-label, dose escalating and expansion clinical trial to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of Lurbinectedin (PM01183) for injection in patients with advanced solid…
- Trial name
- NCT04638491
- Testing
- Lurbinectedin for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Luye Pharma Group Ltd.
Acute Lymphoblastic Leukemia
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
The objectives of the study are to assess the safety and tolerability of a single dose of SHP674 in Japanese participants (dose confirmation) in the tolerability assessment period of Part 1 and to assess the safety…
- Trial name
- NCT04067518
- Testing
- SHP674
- Where
- 8 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Institut de Recherches Internationales Servier
Multiple Myeloma in Relapse, Multiple Myeloma
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
- Trial name
- NCT04184050
- Testing
- MK-4002
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Small Cell Lung Cancer Recurrent
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.
- Trial name
- NCT03823118
- Testing
- S1/Anlotinib
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Taizhou Hospital
Malignant Glioma, Recurrent Glioma
Personalized Vaccine for Patients With Recurrent Malignant Glioma
A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.
- Trial name
- NCT04943718
- Testing
- personalized vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xuanwu Hospital, Beijing
Colon Cancer, Colorectal Cancer
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
The goal of this clinical research study is to find out what effects radioactive particles, SIR-spheres, have when injected into the liver, followed by systemic chemotherapy with a combination of cetuximab and irinotecan compared…
- Trial name
- NCT00766220
- Testing
- SIR-spheres Agent Administration, Cetuximab, Irinotecan
- Sponsor
- M.D. Anderson Cancer Center
Urinary Bladder Neoplasms
HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC
This is a multicenter, randomized controlled clinical trial (HOPE-07) designed to evaluate the efficacy and safety of perioperative treatment with disitamab vedotin (RC48) combined with toripalimab compared with toripalimab…
- Trial name
- HOPE-07-MIBC (NCT07608224)
- Testing
- Disitamab Vedotin (RC48), Gemcitabine + Cisplatin（GC）+Toripalimab, Toripalimab (JS001 )
- Volunteers
- 240 people
- Sponsor
- West China Hospital
Locally Advanced Pancreatic Adenocarcinoma
Immunochemoradiotherapy in Patients With Pancreatic Cancer
This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger…
- Trial name
- NCT01342224
- Testing
- tadalafil and vaccination
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Providence Health & Services
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease
This clinical trial tests a mindfulness intervention, consisting of group sessions and an individual session, using mindfulness based stress reduction techniques, to reduce patient reported symptoms for patients with chronic…
- Conditions
- Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT07733141
- Testing
- Biospecimen Collection, Mindfulness Relaxation, Survey Administration
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- City of Hope Medical Center
Cancer, Breast Cancer
The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer
This study is for people whose cancer: has resisted chemotherapy are taking a break from chemotherapy or are looking for an alternative to the toxic effects of chemotherapy The trial is looking to see if a very low carbohydrate…
- Conditions
- Cancer, Breast Cancer, Colon Cancer, Cervical Cancer
- Trial name
- RECHARGE (NCT00444054)
- Testing
- Very low carbohydrate diet (approximately 20 grams per day)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Albert Einstein College of Medicine
Carcinoma, Non-Small-Cell Lung
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dose for the Phase II step.
- Trial name
- NCT00711594
- Testing
- BIBW 2992 MA2 40mg/day, BIBW 2992 MA2 50mg/day, BIBW 2992 MA2 20mg/day
- Where
- 20 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer Metastatic
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
- Trial name
- NCT01876251
- Testing
- PF-03084014, Docetaxel
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- Pfizer
Colorectal Cancer
S9304A Study of Protein Expression in Tumor Tissue Samples From Patients With Stage II or Stage III Rectal Cancer Enrolled in Clinical Trial SWOG-9304
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00972751
- Volunteers
- 220 people
- Sponsor
- SWOG Cancer Research Network
Polycystic Ovary Syndrome
Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS)
PolysCsytic Ovaries Syndrome (PCOS) is the most frequent endocrinopathy. The first stage of infertility treatment is Clomiphene Citrate which leads to 50 % pregnancies.
- Trial name
- PERCING (NCT00378729)
- Testing
- Metformin and FSHr, Ovarian drilling by FERTILOSCOPY
- Where
- France
- Volunteers
- 252 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Cancer, Glioma
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring.
- Trial name
- NCT00870129
- Testing
- MRI and advanced MRI sequences
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03150329
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Hodgkin's Disease, Lymphoma
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Primary Objective: To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed and resistant classical Hodgkin's lymphoma. Secondary Objectives: 1.
- Trial name
- NCT00129753
- Testing
- Alemtuzumab (Campath-1H)
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
This study will assess the safety and efficacy of vismodegib in patients with relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS).
- Trial name
- NCT01880437
- Testing
- cytarabine, vismodegib
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Adenocarcinoma Metastatic
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
The prognosis for pancreatic cancer remains dismal, with current guidelines favoring FOLFIRINOX or AG (consisting of Gemcitabine and Abraxane) as the primary chemotherapeutic option.
- Trial name
- NCT06396637
- Testing
- Sapropterin Dihydrochloride
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Myeloproliferative Neoplasm
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferative neoplasms.
- Trial name
- NCT04103645
- Testing
- Vactosertib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.